Ozoralizumab
Ozoralizumab
Ozoralizumab (pronounced: oz-or-al-iz-u-mab) is a biopharmaceutical drug that is currently under investigation for its potential therapeutic applications.
Etymology
The name "Ozoralizumab" is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, a type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
Mechanism of Action
Ozoralizumab is a Tumor Necrosis Factor Inhibitor (TNFi). It works by binding to Tumor Necrosis Factor alpha (TNFα), a cell signaling protein (cytokine) that plays a pivotal role in inflammatory responses. By inhibiting TNFα, ozoralizumab can potentially reduce inflammation and modulate the immune response.
Clinical Trials
Ozoralizumab has been investigated in clinical trials for its potential use in treating various autoimmune diseases, including rheumatoid arthritis and psoriatic arthritis. However, as of now, it is not yet approved for use in any country.
Related Terms
- Monoclonal Antibodies
- Tumor Necrosis Factor alpha
- Autoimmune Diseases
- Rheumatoid Arthritis
- Psoriatic Arthritis
External links
- Medical encyclopedia article on Ozoralizumab
- Wikipedia's article - Ozoralizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski